Also known as LY3437943, retatrutide is a triple agonist that targets GLP-1, GIP and glucagon receptors. Retatrutide is currently undergoing phase 3 trials and we expect it to be available as a prescription medication in 2029.
Retatrutide
Price range: $89 through $199
Restock expected: mid to late April.
Prices are in AUD.



Reviews
There are no reviews yet.